Recently, a study by Furuya et al. also revealed that the EGFR mutation status (n = 24 for EGFR mutant and n = 88 for EGFR wild type) might be a positive prognostic factor for PFS in NSCLC patients treated with docetaxel + ramucirumab (mPFS was 5.7 months for the EGFR mutant group compared with 3.6 months for the EGFR wild-type group, HR 0.53, 95 % Cl 0.32–0.87; p = 0.01) [48]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.